Lexaria Bioscience (LEXX) Long-Term Deferred Tax (2011 - 2024)
Lexaria Bioscience (LEXX) posted Long-Term Deferred Tax of $10.7 million for Q3 2024, up 12.01% sequentially from $9.6 million in Q3 2023, and up 12.01% YoY from $9.6 million in Q3 2023.
Lexaria Bioscience (LEXX) Long-Term Deferred Tax (2011 - 2024) Analysis & Trends
Lexaria Bioscience has reported Long-Term Deferred Tax for 6 years, with the latest figure at $10.7 million in Q3 2024.
- Quarterly Long-Term Deferred Tax rose 12.01% year-over-year to $10.7 million in Q3 2024, while the trailing twelve-month figure through Aug 2024 was $10.7 million (up 12.01% YoY) and the FY2024 annual result came in at $10.7 million, up 12.01% from the prior year.
- Long-Term Deferred Tax climbed to $10.7 million in Q3 2024 per LEXX's latest filing, from $9.6 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $10.7 million in Q3 2024 and troughed at $5.6 million in Q3 2020.
- A 4-year average of $8.1 million and a median of $8.1 million in 2021 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2021 and 2024: Long-Term Deferred Tax advanced 18.01% in 2021, then climbed 12.01% in 2024.
- Over 4 years, Long-Term Deferred Tax stood at $5.6 million in 2020, then increased by 18.01% to $6.6 million in 2021, then surged by 45.29% to $9.6 million in 2023, then advanced by 12.01% to $10.7 million in 2024.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $10.7 million, $9.6 million, and $6.6 million for Q3 2024, Q3 2023, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2024 | 10.73 Mn |
| Aug 31, 2023 | 9.58 Mn |
| Aug 31, 2021 | 6.59 Mn |
| Aug 31, 2020 | 5.59 Mn |
| Apr 30, 2012 | 48,871.00 |
| Oct 31, 2011 | 33,092.00 |